CHLORDIAZEPOXIDE
THERAPEUTICS
brands
Class
- Neuroscience-based Nomenclature: GABA positive allosteric modulator (GABA-PAM)
- Benzodiazepine (anxiolytic)
CHLORDIAZEPOXIDE commonly prescribed for
(Bold for FDA approved)
How CHLORDIAZEPOXIDE works
• Binds to benzodiazepine receptors at the GABA-A ligand-gated chloride channel complex
• Enhances the inhibitory effects of GABA
• Boosts chloride conductance through GABA-regulated channels
• Inhibits neuronal activity presumably in amygdala-centered fear circuits to provide therapeutic benefits in anxiety disorders
How long until CHLORDIAZEPOXIDE works
• Some immediate relief with first dosing is common; can take several weeks with daily dosing for maximal therapeutic benefit
SIDE EFFECTS
Notable Side Effects
• Sedation, fatigue, depression
• Dizziness, ataxia, slurred speech, weakness
• Forgetfulness, confusion
• Hyperexcitability, nervousness
• Rare hallucinations, mania
• Rare hypotension
• Hypersalivation, dry mouth
Life Threatening Side Effects
• Respiratory depression, especially when taken with CNS depressants in overdose
• Rare hepatic dysfunction, renal dysfunction, blood dyscrasias
weight gain

unusual
sedation

common
What to do about CHLORDIAZEPOXIDE side effects
• Wait
• Wait
• Wait
• Lower the dose
• Take largest dose at bedtime to avoid sedative effects during the day
• Switch to another agent
• Administer flumazenil if side effects are severe or life-threatening
DOSING AND USE
usual dosage range
• Mild to moderate anxiety: 15–40 mg/day in 3–4 doses
• Severe anxiety: 60–100 mg/day in 3–4 doses
Dosage Forms
• Capsule 2.5 mg, 5 mg, 10 mg, 25 mg
long term use
• Evidence of efficacy for up to 16 weeks
• Risk of dependence, particularly for treatment periods longer than 12 weeks, and especially in patients with past or current polysubstance abuse
habit forming
• Chlordiazepoxide is a Schedule IV drug
• Patients may develop dependence and/or tolerance with long-term use
SPECIAL POPULATIONS
Renal Impairment
• Initial 10–20 mg/day in 2–4 doses; increase as needed
Hepatic Impairment
• Initial 10–20 mg/day in 2–4 doses; increase as needed
Cardiac Impairment
• Benzodiazepines have been used to treat anxiety associated with acute myocardial infarction
Elderly
• Initial 10–20 mg/day in 2–4 doses; increase as needed
• Elderly patients may be more sensitive to sedative effects
Children and Adolescents
• Not recommended for use in children under age 6
• Initial 10–20 mg/day in 2–4 doses; may increase to 20–30 mg/day in 2–3 doses if ineffective
• Hyperactive children should be monitored for paradoxical effects
• Long-term effects of chlordiazepoxide in children/adolescents are unknown
• Should generally receive lower doses and be more closely monitored
Pregnancy
• Effective June 30, 2015, the FDA requires changes to the content and format of pregnancy and lactation information in prescription drug labels, including the elimination of the pregnancy letter categories; the Pregnancy and Lactation Labeling Rule (PLLR or final rule) applies only to prescription drugs and will be phased in gradually for drugs approved on or after June 30, 2001
• Possible increased risk of birth defects when benzodiazepines are taken during pregnancy
• Because of the potential risks, chlordiazepoxide is not generally recommended as treatment for anxiety during pregnancy, especially during first trimester
• Drug should be tapered if discontinued
• Infants whose mothers received a benzodiazepine late in pregnancy may experience withdrawal effects
• Neonatal flaccidity has been reported in infants whose mothers took a benzodiazepine during pregnancy
• Seizures, even mild seizures, may cause harm to the embryo/fetus
Breast Feeding
Unknown if chlordiazepoxide is secreted in human breast milk, but all psychotropics are assumed to be secreted in breast milk
• Recommended either to discontinue drug or bottle feed
• Effects of benzodiazepines on nursing infants have been reported and include feeding difficulties, sedation, and weight loss
Based on data Published online by Cambridge University Press
Compiled by Dr. Jash Ajmera